Calluna Pharma successfully completes Phase 1 clinical study of CAL101, a first-in-class therapeutic for fibrotic and fibro-inflammatory indications

Calluna Pharma AS (Calluna), a clinical stage biotechnology company pioneering first-in-class antibodies to treat inflammatory and fibrotic diseases, today announced the completion of Phase 1 clinical study for CAL101, Calluna’s lead product candidate.

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at

December 12, 2023

AstraZeneca rolls up cardiovascular, renal and metabolic interconnections in film and digital effort

AstraZeneca is putting its cardiovascular, renal and metabolic (CVRM) portfolio in the spotlight with a short film and digital campaign. The two-minute video lays out

September 19, 2023

FDA wants more data from Abeona Therapeutics as it pushes for BLA

Abeona Therapeutics pushed back plans to submit its gene therapy for a rare skin condition after the FDA asked the company for more data about

June 9, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.